Dominik Witzigmann
Overview
Explore the profile of Dominik Witzigmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
3339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pattipeiluhu R, Arias-Alpizar G, Basha G, Chan K, Bussmann J, Sharp T, et al.
Adv Mater
. 2022 Feb;
34(16):e2201095.
PMID: 35218106
Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies are exemplified by Onpattro, an...
12.
Sedighi M, Rahimi F, Shahbazi M, Rezayan A, Kettiger H, Einfalt T, et al.
ACS Appl Bio Mater
. 2022 Jan;
3(1):239-251.
PMID: 35019440
Hepatocellular carcinoma is the most common type of primary malignancy in the liver and one of the most common types of cancer worldwide. Its readily increasing mortality rate highlights the...
13.
Kamanzi A, Gu Y, Tahvildari R, Friedenberger Z, Zhu X, Berti R, et al.
ACS Nano
. 2021 Nov;
15(12):19244-19255.
PMID: 34843205
Nanoparticles are a promising solution for delivery of a wide range of medicines and vaccines. Optimizing their design depends on being able to resolve, understand, and predict biophysical and therapeutic...
14.
Al Fayez N, Bottger R, Rouhollahi E, Cullis P, Witzigmann D, Li S
Mol Pharm
. 2021 Sep;
19(6):1778-1785.
PMID: 34546758
Hemolytic toxicity caused by primaquine (PQ) is a high-risk condition that hampers the wide use of PQ to treat liver-stage malaria. This study demonstrated that phospholipid-free small unilamellar vesicles (PFSUVs)...
15.
Kulkarni J, Witzigmann D, Thomson S, Chen S, Leavitt B, Cullis P, et al.
Nat Nanotechnol
. 2021 Jul;
16(7):841.
PMID: 34194013
No abstract available.
16.
Tam A, Leclair P, Li L, Yang C, Li X, Witzigmann D, et al.
Am J Physiol Lung Cell Mol Physiol
. 2021 Jun;
321(2):L377-L391.
PMID: 34105356
Genome-wide association studies have shown that a gene variant in the Family with sequence similarity 13, member A (FAM13A) is strongly associated with reduced lung function and the appearance of...
17.
Kulkarni J, Witzigmann D, Thomson S, Chen S, Leavitt B, Cullis P, et al.
Nat Nanotechnol
. 2021 Jun;
16(6):630-643.
PMID: 34059811
The increasing number of approved nucleic acid therapeutics demonstrates the potential to treat diseases by targeting their genetic blueprints in vivo. Conventional treatments generally induce therapeutic effects that are transient...
18.
Rothgangl T, Dennis M, Lin P, Oka R, Witzigmann D, Villiger L, et al.
Nat Biotechnol
. 2021 May;
39(8):949-957.
PMID: 34012094
Most known pathogenic point mutations in humans are C•G to T•A substitutions, which can be directly repaired by adenine base editors (ABEs). In this study, we investigated the efficacy and...
19.
Witzigmann D, Grossen P, Quintavalle C, Lanzafame M, Schenk S, Tran X, et al.
J Control Release
. 2021 Apr;
334:138-152.
PMID: 33894304
Hepatocellular carcinoma (HCC) is related to increasing incidence rates and poor clinical outcomes due to lack of efficient treatment options and emerging resistance mechanisms. The aim of the present study...
20.
Chander N, Morstein J, Bolten J, Shemet A, Cullis P, Trauner D, et al.
Small
. 2021 Apr;
17(21):e2008198.
PMID: 33880882
Encapsulation of small molecule drugs in long-circulating lipid nanoparticles (LNPs) can reduce toxic side effects and enhance accumulation at tumor sites. A fundamental problem, however, is the slow release of...